Biomedical subjects

A Tucci

Publications and source records attributed to A Tucci.

57 records · Page 4Linked to original sources

PubMedDate not supplied

[Biologic activity of prostacyclin in patients with malignant tumors of the bones and soft tissues].

Hemostatic diffusion is mediated in part by platelet activation. Prostacyclin (PGI2) is known to be a powerful inhibitor of the aggregation of human platelets in vitro. In this study exogenous PGI2 was incubated in plasma of patients with bone and soft tissue cancer and its inhibiting activity of platelet aggregation was evaluated. Inhibition was found to be significantly lower and of shorter duration in the plasma of the 10 cancer patients tested as compared to the activity in the plasma of the healthy controls. Mechanisms of decreased prostacyclin activity are discussed in relation to the platelets in tumor cell metastases.

Adolescent↗

PubMedDate not supplied

Evaluation of Helicobacter pylori sensitivity to amoxycillin and metronidazole in dyspeptic patients.

We evaluated the "in vitro" sensitivity to amoxycillin and metronidazole of 193 Helicobacter pylori strains isolated from the gastric mucosa of dyspeptic patients. Susceptibility was determined by disc diffusion on agar plates. All the isolates were found to be sensitive to amoxycillin. On the contrary, 12% of the strains isolated from patients never treated for Helicobacter pylori infection and 73% of those isolated from patients who had previously received unsuccessful treatment for Helicobacter pylori infection were found to be resistant to metronidazole. Resistance was more common in women (17%) than in men (4%: p < 0.01) and was not correlated with age. The occurrence of Helicobacter pylori resistance to metronidazole is relatively common in Italy. In vitro testing of Helicobacter pylori sensitivity seems to be important before embarking on treatments aimed at eradicating the bacterium.

Adult↗

PubMedDate not supplied

Study of CD40 ligand expression in B-cell chronic lymphocytic leukemia.

CD40 ligand (CD40L) is a membrane molecule that plays a key role in T cell-B cell cooperation, providing B cells the helper signals needed for activation, proliferation, differentiation and prevention of apoptosis. Patients with B-cell chronic lymphocytic leukemia (B-CLL) were studied to verify the following hypotheses: a) whether defective CD40L expression on activated T cells could account for deficient helper signals and therefore for hypogammaglobulinemia; b) whether aberrant CD40L expression on B cells could be a mechanism by which leukemic cells stimulate themselves via CD40 to escape apoptosis. Results showed physiological expression of CD40L on in vitro activated CD4+ cells, while this expression was absent on fresh and activated B cells. Abnormalities in CD40/CD40L interaction do not seem to play a role either in the pathogenesis of hypogammaglobulinemia or in lymphocyte accumulation in B-CLL.

Adult↗